In particular, gemcitabine-resistant pancreatic cancer acquired EMT properties and a CSC phenotype through Jagged1–Notch2 (89), suggesting that inactivation of Notch may be a potential therapeutic approach to overcome chemoresistance in invasive and metastatic pancreatic cancer. Here, NOTCH2 is linked to pancreatic neoplasm.